^
    8d
    HMPL-012-SPRING-P105: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: May 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    8d
    HMPL-012-SPRING-OS101: Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Sulanda (surufatinib)
    8d
    HMPL-012-SPRING-NEN109: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=6, Terminated, Changhai Hospital | N=100 --> 6 | Trial completion date: Nov 2026 --> Jun 2026 | Not yet recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jun 2026; This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Sulanda (surufatinib)
    23d
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    1m
    A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=190, Completed, Hutchison Medipharma Limited | Recruiting --> Completed | N=141 --> 190 | Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Sep 2024 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • fanregratinib (HMPL-453)
    2ms
    Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. (PubMed, Signal Transduct Target Ther)
    Combining a GPR34 antagonist with chemotherapy and surufatinib significantly enhanced anti-tumor responses in preclinical models. These findings identify GPR34 as a promising immune therapeutic target.
    Journal
    |
    CD8 (cluster of differentiation 8) • CSF1R (Colony stimulating factor 1 receptor)
    |
    Sulanda (surufatinib)
    2ms
    A machine learning-driven framework integrating cell death and senescence signatures for multi-target drug design and immunotherapy optimization in ovarian cancer. (PubMed, NPJ Precis Oncol)
    Drug sensitivity analysis linked CDSLS to differential responses to brivanib, azacitidine, and other agents. Our framework supports the use of AI in identifying conserved binding sites, predicting mutational escape, and provide a basis for future analysis for OC.
    Journal • IO biomarker
    |
    RB1 (RB Transcriptional Corepressor 1) • CD8 (cluster of differentiation 8)
    |
    azacitidine • brivanib alaninate (BMS-582664)
    2ms
    Efficacy and Safety of Surufatinib in Treating Pituitary Neuroendocrine Tumors: A Single-Center, Single-Arm, Exploratory Study (ChiCTR2600120740)
    P=N/A, N=40, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    Sulanda (surufatinib)
    2ms
    Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, West China Hospital
    New trial
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Sulanda (surufatinib)
    3ms
    STARS-RC10: Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria (clinicaltrials.gov)
    P2/3, N=212, Recruiting, The First Hospital of Jilin University
    New P2/3 trial
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • Sulanda (surufatinib)
    3ms
    A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    segigratinib (3D185)
    3ms
    Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • Sulanda (surufatinib)